Figure 2. Time to Next Treatment for Ibrutinib Versus CIT (A) and BR (B)^{1, 2}.

Abbreviations: BR = bendamustine/rituximab; CI = confidence interval; CIT = chemoimmunotherapy. Notes: ^*Indicates P-value < .05. ¹Weighted populations were obtained by using inverse probability of treatment weights. The inverse probability of treatment weights were estimated based on propensity score. Variables used in the propensity score calculation included the following baseline characteristics: age, gender, United States region, month and year of index date, insurance plan type, time from first chronic lymphocytic leukemia diagnosis to index date, Charlson comorbidity index, baseline comorbidities (hypertension, lymphoma, deficiency anemias, diabetes, coagulation deficiency, chronic pulmonary disease), and baseline use of corticosteroids. ²Hazard ratios were calculated using weighted Cox proportional hazards regression models adjusted for baseline total all-cause costs.